play3cardpoker| Shanghai has included assisted reproduction in medical insurance, and the sector has risen accordingly. Hanshang Group and Yuexin Health both have daily limits.

May 22play3cardpokerThe concept of assisted reproduction has risen. Hanshang Group (600774) and Yuexin Health (002162) have daily limits, Aoyang Health (002172), Dajia Vikang (301126), Toujing Life (300642), Kyodo Pharmaceutical (300966), Adoption Shares (301122), Medi Technology (603990), etc. have rapidly followed suit.

[Sector daily limit for individual stocks]

Hanshang Group (600774), price limit: 8play3cardpoker.42 yuan/share, P/E ratio: 49play3cardpoker.01, total market value: 2.484 billion.

Yuexin Health (002162), trading price: 3.91 yuan/share, P/E ratio: -69.57, total market value: 3.623 billion.

[Reason for the change: Shanghai City has included 12 assisted reproductive medical service items in the scope of medical insurance payment]

Today, the concept stocks of assisted reproduction have moved up. As of press time, Hanshang Group and Yuexin Health have both traded at daily limits.

Hanshang Group, as a diversified medical and health company, has layout in the fields of assisted reproduction, polylactic acid materials and medical devices.

In the field of assisted reproduction, Hanshang Group directly and indirectly holds 76% of the capital contribution of Huake Reproductive Hospital. Huake Reproductive Hospital not only undertakes sub-project research of the China Population and Development Research Center project, but also is awarded the title of "Expert Unit" and "Fertility Ability Intelligent Evaluation Center". The hospital has the only human sperm bank in Hubei Province and the fertility preservation center in Hubei Province, which provides the company with the help of the field of assisted reproduction.play3cardpokerIt has a solid foundation and competitive advantages.

In addition, Hanshang Group further strengthened its control over Huake Reproductive Hospital by obtaining an 81.34% equity of Wuhan Tongji Technology Group Co., Ltd., the investor of Huake Reproductive Hospital. The privatization reform of Tongji Science and Technology Group will help transform reproductive hospitals from non-profit institutions into for-profit enterprises.

In the field of medical devices, Hanshang Group's business is mainly absorbable biomedical materials, and also covers bioactive wound repair, minimally invasive and interventional treatment devices. Dikang Zhongke, a subsidiary of the company, is a leading domestic producer of medical-grade polylactic acid materials capable of large-scale production, and has completed the evaluation of the scientific and technological achievements of the polylactic acid microsphere project. The company's R & D and production capabilities in the field of medical materials are both industry-leading position.

Tags：

Article Copyright Statement: Unless otherwise specified, all articles are jiliasia16 com original. Reproduction or reproduction should be in the form of hyperlinks and indicate the source.